Exploring a Breakthrough: Bayer’s Phase III Study of Oral FXIa Inhibitor Asundexian

Attention: Not intended for U.S. and UK Media

Exciting news out of Berlin! Bayer has just unveiled the launch of a Phase III clinical development program called “OCEANIC.” This initiative aims to explore the potential effectiveness and safety of asundexian, a groundbreaking oral Factor XIa (FXIa) inhibitor. The goal? To evaluate its potential as a new treatment for patients with atrial fibrillation, non-cardioembolic ischemic stroke, or high-risk transient ischemic attack.

What makes Factor XI so promising? It’s a protein in the blood that plays a critical role in the blood coagulation cascade. The focus on developing safer anticoagulants by targeting Factor XI is due to its role in pathological versus normal thrombus formation, ultimately separating hemostasis from thrombosis. The OCEANIC program aims to determine if asundexian can protect patients from pathological thrombus formation, without increasing the risk of bleeding, thus improving the current benefit-risk profile compared to existing treatment options.

The OCEANIC program’s launch is attributable to the data from the Phase II PACIFIC program. The completed PACIFIC Phase IIb clinical trial program demonstrated consistent safety results for asundexian compared to the placebo arm. This includes encouraging bleeding data, suggesting that asundexian may prevent thromboembolic events without increasing bleeding risk – potentially a game-changer in patient care.

“With deep experience and disease understanding, Bayer is particularly strong in the field of anticoagulation and has made significant contributions to the lives of over 100 million patients. To discover more about the Phase III study program for asundexian, click here. And for an in-depth look at the exciting potential of this new treatment, Read More